GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (OTCPK:TRVN) » Definitions » Net Current Asset Value

TRVN (Trevena) Net Current Asset Value : $-32.47 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Trevena Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Trevena's net current asset value per share for the quarter that ended in Sep. 2024 was $-32.47.

The historical rank and industry rank for Trevena's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Trevena was 4.58. The lowest was 0.96. And the median was 3.16.

TRVN's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.865
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Trevena Net Current Asset Value Historical Data

The historical data trend for Trevena's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevena Net Current Asset Value Chart

Trevena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 136.24 372.55 208.41 25.57 -18.87

Trevena Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.58 -18.87 -27.03 -27.98 -32.47

Competitive Comparison of Trevena's Net Current Asset Value

For the Biotechnology subindustry, Trevena's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevena's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevena's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Trevena's Price-to-Net-Current-Asset-Value falls into.


;
;

Trevena Net Current Asset Value Calculation

Trevena's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(35.205-48.262-0-0)/0.692
=-18.87

Trevena's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2024 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(14.735-42.497-0-0)/0.855
=-32.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trevena  (OTCPK:TRVN) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Trevena Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Trevena's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Trevena Business Description

Traded in Other Exchanges
N/A
Address
955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, USA, 19087
Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
Executives
Mark Corrigan director
Mark Demitrack officer: SVP, Chief Medical Officer 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Robert T Yoder officer: SVP, Chief Business Officer 955 CHESTERBROOK BOULEVARD, SUITE 110, SUITE 200, CHESTERBROOK PA 19087
Carrie L. Bourdow director, officer: President & CEO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Patricia M. Drake officer: SVP, Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Barry Shin officer: SVP, CFO C/O TREVENA, INC., 955 CHESTERBROOK BLVD, SUITE 110, CHESTERBROOK PA 19087
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Scott Applebaum officer: CLCO; SVP, Regulatory Affairs C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
John P. Hamill officer: Int. Prin. Fin. Off. and PAO 4092 NEW HOPE ROAD, FURLONG PA 18925

Trevena Headlines

From GuruFocus

Q1 2022 Trevena Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2021 Trevena Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2023 Trevena Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Trevena Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2022 Trevena Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Trevena Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2021 Trevena Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024